{
  "id": 20740307,
  "title": "STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment",
  "url": "https://urgent.news/2026/11/19/stat-in-cancer-drug-development-the-spotlight-shifts-onto-erascas",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T11:30:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/"
  },
  "original_language": "en",
  "account": "Erasca, a U.S.-based biotech company, is touting its KRAS-targeted treatment, ERAS-0015, as a potentially more potent and better-tolerated pan-RAS inhibitor compared to Revolution Medicines' Rasonque. The company has backed up this claim with limited data from an early-stage study, but its valuation remains a fraction of Revolution Medicines' $35 billion market value. Erasca is set to present more data on ERAS-0015 at the EORTC-NCI-AACR “Triple” meeting in Barcelona, with CEO Jonathan Lim signaling a potentially significant response rate in second-line pancreatic cancer.",
  "summary": "Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?",
  "key_points": [
    "Erasca's ERAS-0015 targets KRAS in cancer drug development",
    "Early-stage study supports ERAS-0015 as potent pan-RAS inhibitor",
    "CEO Jonathan Lim anticipates significant response rate in pancreatic cancer"
  ],
  "editors_take": "Erasca’s pursuit of a superior pan-RAS inhibitor signals an intensifying competitive race to establish a more potent and tolerable standard of care for difficult-to-treat pancreatic cancer patients.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}